Interview with Bertrand Baron, CEO, Sanofi Mexico
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Address: Av. Universidad N° 1738
Col. Coyoacán
04000 México, D.F.
Tel: 54 84 44 00
Web: http://www.sanofi.com.mx/l/mx/sp/index.jsp
Present in more than 100 countries, with around 11,000 scientists, Sanofi has around 100,000 employees working to improve health and wellbeing. Sanofi’s global headquarters are in Paris, France. Sanofi in Mexico counts on nine major therapeutic areas and its own line of generic medicines.
Sanofi focuses its activities on 9 major therapeutic areas: Cardiovascular, Thrombosis, Diabetes, Oncology, Central Nervous System, Internal Medicine, Vaccines, OTC and Personal Health Care
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
Enrique Giraud de Haro, President & GM at Fujifilm Mexico, highlights the company’s growth alongside Fujifilm’s expansion in the region. He discusses the importance of fostering a preventive healthcare culture,…
Some 16 percent of Mexico’s population is battling diabetes—a number that represents one in five of the nation’s populace without including the vast numbers of undiagnosed Mexicans living with the…
See our Cookie Privacy Policy Here
